SURMOUNT-1 in plain English: what the trial actually showed

SURMOUNT-1 was published in the New England Journal of Medicine in July 2022. It is the trial that moved tirzepatide from "diabetes drug with weight-loss side effects" to "weight-loss drug first." Here is the plain-English version.

What they tested

• Drug: Tirzepatide at three doses (5 mg, 10 mg, 15 mg weekly), subcutaneous injection, plus placebo for comparison
• Population: 2,539 adults with BMI ≥30, or BMI ≥27 with at least one comorbidity. No type 2 diabetes. Mean BMI around 38.
• Duration: 72 weeks (just over 16 months)
• Baseline: mean body weight about 105 kg

What they found

The headline number:

• Placebo group: about 3% body-weight loss (normal for lifestyle + placebo in a structured trial)
• Tirzepatide 5 mg: about 15% body-weight loss
• Tirzepatide 10 mg: about 19.5% body-weight loss
• Tirzepatide 15 mg: about 20.9% body-weight loss

Put differently: in the 15 mg group, the average participant lost about 22 kg. More than half lost at least 20% of starting body weight. Roughly a third lost at least 25%. A small but meaningful subset lost 30% or more.

These are unusual numbers for a non-surgical intervention. They are why the medical community reset its expectations for what pharmacology can do for obesity.

The parts the press usually skips

Muscle mass. Weight loss includes both fat and lean mass. In SURMOUNT-1 and related trials, approximately 25-40% of the weight lost is lean mass (muscle, connective tissue, organ mass) depending on the subgroup. This means a participant losing 22 kg loses roughly 5 to 9 kg of lean mass in addition to fat. This is a real tradeoff that requires dietary protein and resistance training to mitigate. The trial did not aggressively intervene on this.

Who dropped out. About 17% of tirzepatide participants discontinued treatment, mostly for GI side effects. About 3% discontinued for placebo. This is not dramatic compared to other obesity drugs but it is not zero.

Weight regain after stopping. The trial did not include a post-treatment follow-up arm, but related trials (SURMOUNT-4) showed that weight is substantially regained within a year of stopping. This is not a criticism of the drug; it is how appetite regulation works in the absence of ongoing input.

Cardiovascular outcomes. SURMOUNT-1 was primarily a weight-loss trial, not a cardiovascular outcomes trial. It measured cardiovascular risk factors (blood pressure, lipid panel, A1c) but did not power a hard endpoint (heart attack, stroke, death). Those data are coming from SURPASS and follow-on trials.

Placebo-group lifestyle intervention. Both arms received structured lifestyle counseling. The 3% loss in the placebo arm is what a motivated participant can do with counseling alone over 72 weeks. That is a useful baseline to remember when judging the drug effect.

The safety profile

Adverse events matched expectations for GLP-1 class drugs:

• Mild to moderate GI symptoms: nausea (up to 33%), diarrhea (up to 23%), vomiting (up to 13%), constipation (up to 12%). These were mostly during titration and resolved for most participants.
• Injection-site reactions: infrequent and mild.
• Serious adverse events: not significantly different from placebo overall.
• Notable specific events: a small number of pancreatitis cases, a small number of gallbladder events, no thyroid C-cell tumors observed. The thyroid warning remains in the label based on rat data.

How clinicians read it

Two common interpretations:

1. Tirzepatide is the new benchmark for pharmacological weight loss in patients who meet the indication. It beats semaglutide in head-to-head dosing. It produces outcomes that approach what bariatric surgery achieves for some patients.

2. The drug works; the question is patient selection and durability. The 72-week trial does not tell us what happens at year 5. The lean-mass loss question is not fully addressed by the trial design. The cost of chronic use is nontrivial. Who should use it, for how long, and with what supporting protocol remains a clinical judgment, not a trial-determined fact.

Both interpretations are compatible. The drug works. The surrounding protocol matters.

Where to read more

• The SURMOUNT-1 paper, NEJM 2022 (open access)
• Peter Attia's coverage of the tirzepatide data on The Drive
• Huberman's long-form conversation with Sean O'Mara on GLP-1 dosing

If you want a routed match

Take the quiz. Two minutes. We email you a match within 24 to 48 hours.